NO944013L - Endothelin Antagonists II - Google Patents

Endothelin Antagonists II

Info

Publication number
NO944013L
NO944013L NO944013A NO944013A NO944013L NO 944013 L NO944013 L NO 944013L NO 944013 A NO944013 A NO 944013A NO 944013 A NO944013 A NO 944013A NO 944013 L NO944013 L NO 944013L
Authority
NO
Norway
Prior art keywords
disease
endothelin
diabetes
ischemic
hypertension
Prior art date
Application number
NO944013A
Other languages
Norwegian (no)
Other versions
NO944013D0 (en
Inventor
Wayne Livingston Cody
John Gordon Topliss
Annette Marian Doherty
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO944013L publication Critical patent/NO944013L/en
Publication of NO944013D0 publication Critical patent/NO944013D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

Det beskrives nye antagonister av endothelin, samt frem- gangsmåter for fremstilling av slike og farmasøytiske preparater av disse, som er anvendelige ved behandling av forhøyede nivåer av endothelin, akutt og kronisk nyresvikt, hypertensjon, myokardinfarkt, metabolske, endokrine og nevrologiske forstyrrelser, kongestiv hjertesvikt, endotoksisk sjokk, subarachnoidalblødning, arytmier, astma, preeklampsi, aterosklerotiske forstyrrelser innbefattet Raynauds sykdom, restenose, angina, cancer, pulmonal hypertensjon, ischemisk sykdom, slimhinneskade på mavesekken, blødningssjokk, ischemisk tarmsykdom og diabetes.New antagonists of endothelin are disclosed, as well as methods for the preparation of such and pharmaceutical compositions useful in the treatment of elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrine and neurological disorders, congestive heart disease. , endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, pre-eclampsia, atherosclerotic disorders including Raynaud's disease, restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic diabetes, ischemic diabetes.

NO944013A 1992-04-22 1994-10-21 Endothelin Antagonists II NO944013D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87222592A 1992-04-22 1992-04-22
US3351593A 1993-03-31 1993-03-31
PCT/US1993/003658 WO1993021219A1 (en) 1992-04-22 1993-04-16 Endothelin antagonists ii

Publications (2)

Publication Number Publication Date
NO944013L true NO944013L (en) 1994-10-21
NO944013D0 NO944013D0 (en) 1994-10-21

Family

ID=26709808

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944013A NO944013D0 (en) 1992-04-22 1994-10-21 Endothelin Antagonists II

Country Status (12)

Country Link
EP (1) EP0647236A1 (en)
JP (1) JPH07505890A (en)
KR (1) KR950701344A (en)
AU (1) AU678357B2 (en)
CA (1) CA2133090A1 (en)
CZ (1) CZ256994A3 (en)
FI (1) FI944905A (en)
HU (1) HUT68862A (en)
NO (1) NO944013D0 (en)
NZ (1) NZ252855A (en)
SK (1) SK128794A3 (en)
WO (1) WO1993021219A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
UA58494C2 (en) * 1995-06-07 2003-08-15 Зенека Лімітед N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical composition, process for preparing thereof and method for endothelin influence counteraction
US5688499A (en) * 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer

Also Published As

Publication number Publication date
CA2133090A1 (en) 1993-10-28
KR950701344A (en) 1995-03-23
HUT68862A (en) 1995-08-28
HU9403017D0 (en) 1994-12-28
SK128794A3 (en) 1995-03-08
FI944905A0 (en) 1994-10-19
WO1993021219A1 (en) 1993-10-28
AU4290493A (en) 1993-11-18
FI944905A (en) 1994-10-19
JPH07505890A (en) 1995-06-29
AU678357B2 (en) 1997-05-29
EP0647236A1 (en) 1995-04-12
NO944013D0 (en) 1994-10-21
CZ256994A3 (en) 1995-02-15
NZ252855A (en) 1996-11-26

Similar Documents

Publication Publication Date Title
MX9308191A (en) ENDOTHELINE ANTAGONISTS.
GR3032643T3 (en) Phenoxyphenylacetic acid derivatives.
TR200100500T2 (en) Therapies for the treatment of pulmonary diseases
NO944013L (en) Endothelin Antagonists II
ATE195948T1 (en) ENDOTHELIN ANTAGONISTS
NO20000411L (en) 4-Amino-phenylalamine compounds that inhibit leukocyte adhesion mediated by VLA-4
HU9501229D0 (en) Dithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases
NO986090L (en) Phenylalanine derivatives as integrin inhibitors
DK1054887T3 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists
WO2002057439A3 (en) Plant transcription factors
CA2080705A1 (en) Substituted pyrimidines
WO2003042214A3 (en) A2b adenosine receptor antagonists
CA2104909A1 (en) Decahydroisoquinolines as excitatory amino acid receptor antagonists
DE69528711D1 (en) CHINAZOLINES AS INHIBITORS OF THE ENDOTHELINE CONVERTING ENZYME
PL321866A1 (en) Benzothiazine dioxides as endothelin antagonista
EP0318083A3 (en) Pyridyl dialkanoic acids and their use as medicaments
FI914906A0 (en) 1- (3,4-DIHYDRO-2-OXO-1H-QUINOLIN-6-YL) -2- (4- (2-PHENYLTHYL) PIPERIDIN-1-YL) ETHANOL OCH-ETHANONE, DERAS FRAMSTAELLNING OCH ANVAENDNING INOM THERAPY.
AU6670196A (en) Thienopyrimidine derivatives, their production and use
Sapino RSR Steel, Investor Group Buy Bayou Steel for$ 76 M
MONRO et al. JOHN LINDSAY STEVEN, MD
n'Roses Paradise city
CA2464289A1 (en) Heterocyclic retinoid compounds
Pack JPAM's fifteenth year
Withiam A critical crossroads for the industry, says KPMG
Navarro Foreign Firms Show Interest In Buying Government-owned Compania Minera Autlan